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Abstract 54 
Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient 55 
sample size and power, have been enormously successful. The Psychiatric 56 
Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will 57 
grow to (cumulatively) >1 million individuals in the next 5 years. This should lead to 58 
hundreds of new findings for common genetic variants across nine psychiatric 59 
disorders studied by the PGC. The new targets discovered by GWAS have the 60 
potential to restart largely stalled psychiatric drug development pipelines, and the 61 
translation of GWAS findings into the clinic is a key aim of the recently funded phase 62 
3 of the PGC. This is not without considerable technical challenges. These 63 
approaches complement the other main aim of GWAS studies on risk prediction 64 
approaches for improving detection, differential diagnosis, and clinical trial design. 65 
This paper outlines the motivations, technical and analytical issues, and the plans for 66 
translating PGC3 findings into new therapeutics. 67 
  68 
The state of drug discovery in psychiatry. 69 
In psychiatry, conventional drug discovery is at an impasse 1. In 2015, three 70 
(cariprazine, aripiprazole lauroxil, and brexpiprazole) out of 45 new drugs approved 71 
by FDA were related to psychiatry. The mechanisms of action of these drugs are not 72 
novel as their pharmacology primarily targets dopamine and serotonin receptors. 73 
There still remain significant unmet medical needs and societal costs for psychiatric 74 
disorders that necessitate novel therapeutics. 2 In disorders where partially effective 75 
treatments already exist, drug development has a higher investment risk, because 76 
any new drug has to exceed the clinical efficacy of existing treatments, or show 77 
equivalent efficacy together with significant improvements in safety and tolerability, 78 
as well as competing for market share with established standards of care. This is 79 
particularly difficult where there is a lack of novel targets with adequate validation. 80 
This has resulted in relatively higher drug discovery and development costs and 81 
longer than average cycle time in both clinical trial execution and regulatory agency 82 
review. Some companies have paused or de-prioritised their drug discovery and 83 
clinical trial efforts in psychiatry 3. However, there are many (183) clinical trials 84 
underway or registered, showing there is still considerable investment in the field. 85 
(Supp Table 1 provides details of current and recent trials in psychiatry, including the 86 
nine PGC3 disorders).  87 
The challenges in developing novel therapeutics for psychiatric disorders result from 88 
the paucity of novel, valid targets. This results from etiological heterogeneity, the 89 
complex and polygenic nature of genetic risk and the definition of psychiatric 90 
disorders based on the range and duration of symptoms (that are subjective, self-91 
reported or observational). In addition, the complexity of the human brain means that 92 
large gaps exist in our knowledge of how brain expressed biochemical pathways 93 
relate to identified brain circuits and neuronal networks. The few examples of 94 
aetiology relevant higher order human behavioural functional domains and 95 
behavioural quantitative trait dimensions 4 limit the potential targets and measurable 96 
readouts that can used in animal and human experimental medicine studies. .While 97 
target identification based on genetics and biology looks increasingly feasible, 98 
concerns about the validity of existing model systems, especially rodents, have 99 
hampered the assessment of the value of potential new drug targets (target 100 
qualification) and have led to calls for proof of concept human studies as the ultimate 101 
approach in hypothesis testing for target validation. 5 However clinical proof-of 102 
concept validation studies are expensive and carry risk, and will always be limited in 103 
number. Other challenges arise from the lack of informative biomarkers to guide 104 
proof of concept clinical studies and clinical development (for example by patient 105 
stratification), subjective clinical endpoints, and high placebo response rates 106 
(particularly in major depression) {Shorter, 2011 #629}.  107 
What can genetic studies offer for drug discovery? 108 
Human genetic studies have made tremendous progress in identifying loci linked to 109 
human disorders. Outside of psychiatry, these include high-risk mutations in single 110 
genes that identify specific targets for manipulation4. These include PCSK9, where 111 
individuals with ‘knockout’ mutations have lower LDL cholesterol without obvious 112 
deleterious effects, that has led to promising results in clinical trials 6, loss of function 113 
mutations in SLC30A8 7 which reduce the risk of type 2 diabetes, and loss of 114 
function LPA mutations which reduce plasma lipoprotein(a) levels and cardiovascular 115 
disease risk. 8  116 
With the notable exception of autism with intellectual disability, however, rare 117 
mutations account for a relatively small proportion of cases in psychiatry, although 118 
this varies among disorders and their exact contribution is debated. Where they have 119 
been found, there is evidence that they converge on the same biological pathways 120 
as common variants: genes in schizophrenia GWAS associated regions overlap with 121 
those identified by sequencing studies focussed on de-novo damaging mutations in 122 
intellectual disability and autism 9 10 11. 123 
It may be more straightforward to identify a new target via rare mutations, but it is 124 
often not clear whether manipulating these targets will be effective in the wider 125 
disease population. The common disease-associated polymorphisms identified by 126 
GWAS in psychiatry and other complex disorders also have the potential to identify 127 
novel drug targets as well as new aetiologies that can kindle the generation of new 128 
model systems for therapeutic development in the wider population. 12 Several 129 
examples indicate that although GWAS loci have small effect sizes, they 130 
nonetheless may help identify targets for novel therapeutics, as shown in GWAS 131 
meta-analyses of lipid levels, 13 or existing drugs that can be repurposed for the 132 
treatment of diseases that they were not initially developed to treat, an approach 133 
known as drug repositioning 14,15. Integration of genetic data can be used for target 134 
selection, matching targets to indications while allowing a reduction in clinical trial 135 
costs such as by allowing more accurate identification of high risk individuals. 136 
Targets with genetic support have been shown to have a higher chance of success 137 
16. 138 
What genomics can offer 139 
The discovery of common genetic variants associated with risk for psychiatric illness 140 
has the capability of restarting hypothesis-led drug discovery. As for other complex 141 
genetic disorders, the application of human genetics to schizophrenia, led by the 142 
PGC (URLs), has identified multiple disease susceptibility loci with increasing 143 
sample sizes. In 2014, over 100 robustly associated loci were identified through 144 
case-control GWAS meta-analysis by the PGC 9. Similar progress is underway in 145 
other psychiatric disorders, with new successful GWAS reports expected for ADHD, 146 
autism, major depressive disorder, anorexia nervosa, and bipolar disorder in the next 147 
year.  148 
The discovery of GWAS loci for these disorders is likely to continue for many years 149 
to come with, ultimately, many hundreds or thousands of independent genetic 150 
associations expected for each disorder 17. This does not mean the whole genome 151 
will eventually be implicated - rather we expect thousands of physically overlapping 152 
and independently associated loci to cluster onto hundreds of gene regions. The 153 
available evidence suggests these hits will converge onto both specific genes and 154 
biological pathways. 155 
Insight into which genes (and which gene-products) are implicated and the direction 156 
of effect is needed to determine the most appropriate therapeutic strategy. A general 157 
understanding of the additional steps in the target identification and qualification 158 
process has developed: GWAS locus-to-gene mapping to determine which gene(s) 159 
give rise to the association, plus functional studies of how the disease-associated 160 
SNPs operate (modality), either via regulatory effects (e.g. affecting RNA splicing or 161 
levels) or through direct functional effects (affecting the nature and function of a 162 
protein). In this way, therapeutics targeting single GWAS identified targets, such as 163 
HMGCR in the LDL cholesterol metabolism responsible for hypercholesterolemia 18, 164 
have been successfully developed. This process is beginning for schizophrenia 19, 165 
and the PGC aims to accelerate this for all psychiatric disorders. 166 
One problem is that GWAS hits identify variants, usually SNPs, that mark regions of 167 
the genome, so-called ‘loci’, but in most cases do not directly identify the genes 168 
themselves nor their causal alleles. A GWAS locus often includes multiple genes 169 
within the region of statistical significance, and a hit within a gene does not 170 
guarantee that that is the gene involved; the functional effect of the variants is not 171 
usually obvious, and it may even have a regulatory effect on a gene outside the 172 
GWAS risk locus. Data from large scale genomic and systems biology experiments 173 
are being used to identify expression, protein and methylation quantitative trait loci 174 
(e, p and m-QTLs) to try to better map causal alleles 20 21. This includes imputation of 175 
gene expression profiles 22 23. A caveat is that linkage disequilibrium between 176 
markers often results in multiple genes in a region being implicated by expression 177 
imputation, recapitulating the initial problem. In addition, the lack of large samples of 178 
available brain tissues from both patients and healthy donors at appropriate stages 179 
of development as yet hampers the wide scale application of this approach, although 180 
the CommonMind (http://commonmind.org) and Brainseq 24 initiatives are taking 181 
strides in this direction (discussed below). It remains the case that each GWAS locus 182 
requires careful and bespoke examination (see Geschwind et al this issue 25).). 183 
The available data indicate that psychiatric disorders are highly ‘polygenic’ and we 184 
now expect hundreds or thousands of individual variants to be associated with each 185 
disorder. A promising strategy to deal with the small effect sizes and plethora of 186 
results is to adopt a pathway- and network-informed interpretation of GWAS hits. An 187 
analysis by Cao and Moult 26 found that while only a small fraction of known drug 188 
targets are in GWAS loci (12 of 353 drug targets for 81 diseases), known drug 189 
targets are enriched three-fold in the nearest neighbour interactors (proteins that 190 
physically interact with a given protein) of genes in GWAS loci and are also enriched 191 
in second order interactors. This is supported by GWAS results in type 2 diabetes 27 192 
which found that pathways targeted by anti-diabetes drugs are enriched in genes 193 
from GWAS and their direct protein interactors. This pool of GWAS hits, their 194 
interacting partners and networks provides a resource for the identification of novel 195 
drug targets and for drug repositioning. 196 
How can genetic and genomic data be used in the psychiatric drug 197 
development pipelines?  198 
A critical issue in the field is how to use genetics information to drive drug discovery. 199 
As reviewed above, it often is not clear what genes are driving the association for 200 
GWAS significant loci. A potentially paradigmic example has recently emerged. C4 201 
copy number was recently confirmed as a schizophrenia risk locus potentially 202 
affecting synaptic pruning in neurodevelopment; this study used PGC2 203 
schizophrenia GWAS data, expression data from 700 postmortem brains, and 204 
genetic engineering of mice to confirm a potential mechanism 19. This is already 205 
encouraging the development of new therapeutics, because synaptic pruning occurs 206 
as the brain develops to full maturity in the late teens/early adulthood, providing time 207 
during which therapeutic interventions may be possible.  208 
Relatively few GWAS hits have thus far been studied in such detail. However, much 209 
GWAS evidence converges on particular biological pathways which are in 210 
themselves more druggable than single genes 28. The pharmaceutical industry has 211 
also embarked on efforts to understand gene associations and the biological 212 
pathways impacted 5. We need to link risk loci information to our understanding of 213 
pathways to help identify relevant biological processes, cell-types and brain circuits 214 
and to hone in on new molecular hypotheses and possible novel targets 29. This 215 
need has sparked several academic projects and industry-academia pre-competitive 216 
collaborations. There are currently a large number of open-source and/or publically 217 
available efforts. These include large databases, ranging from ChEMBL. DiGB, Drug 218 
Bank to KiDB from the Psychoactive Drug Screening Program (listed in Table c), 219 
which serve as portals for identifying known molecular targets of drugs and drug-like 220 
small molecules. PHAROS (https://pharos.nih.gov/idg/index; http://targetcentral.ws/) 221 
is a new resource enabled by the NIH Druggable Genome Initiative, which serves as 222 
a portal for a variety of useful information regarding druggable targets. Likewise the 223 
Open Targets (formerly the Centre for Therapeutic Target Validation) public-private 224 
initiative in the UK integrates a large number of data sources into one searchable 225 
platform for single targets (https://www.targetvalidation.org/). 226 
In order to enable the integration of functional genomic data from post-mortem brain 227 
samples from cases and controls new technologies are needed that enable the 228 
accurate identification of cell type specific omics profiles and individual level 229 
neuronal circuitry. Key examples driving the generation of large relevant datasets are 230 
industry-academia partnerships including the BrainSeq 24, CommonMind (URLs), 231 
and psychENCODE (URLs) projects, which allow investigators to map genes 232 
identified in GWAS onto transcriptomics in postmortem tissue from controls and 233 
cases with schizophrenia or bipolar disorder (as well as iPSC neuronal cell lines from 234 
cases and controls 30). A primary goal is to elucidate molecular mechanisms driven 235 
by risk variants with the additional benefit that using genetic data can allow causal 236 
anchoring of molecular changes and pathology thus avoiding incidental, downstream 237 
effects of the disorders themselves and their treatments 24.  238 
In order to advance our ability to understand GWAS data, the field will need to 239 
undertake further large-scale efforts to generate sufficient functional characterization 240 
of changes in brain gene and protein expression in patients and during development, 241 
and to move beyond schizophrenia and bipolar disorder to address many other 242 
disorders. The exploration and availability of large patient data sets is valuable. 243 
There are a number of initiatives in large, deeply phenotyped longitudinal samples 244 
aimed at mapping psychiatric genetic discoveries onto imaging, neurophysiological, 245 
and behavioral traits, to establish aetiologically related intermediate phenotypes that 246 
could be useful in the development of novel therapeutics. These and many other 247 
efforts aimed at linking genetic variations associated with risk with circuitry and 248 
molecular targets are a needed next step. 249 
  250 
 251 
Table 1 Large and commonly used chemoinformatics resources. 252 
Precision medicine for psychiatry and polygenic risk scores. 253 
The customization of diagnosis and treatment to individuals - is likely to have a role 254 
in clinical psychiatry. However, the extent to which this will be important and the 255 
proportions of individuals with a particular psychiatric disorder who might benefit 256 
from precision medicine is unclear and is now the subject of considerable research. 257 
Genomics is an important tool in the precision medicine toolbox. It is already 258 
important for several disorders and becoming common in clinical practice (e.g., in the 259 
evaluation of children with intellectual disability and pervasive developmental delay). 260 
However, these studies are mostly focused upon rare genetic variants of 261 
Name Bioactivities Link Summary
Last 
updated
ChEMBL
Various bioactivities (Ki, 
EC50…)
https://www.ebi.ac.uk/chembl/
~1.6M compounds, 14M 
activities, 11K targets 2016
Ki DB Ki 
http://kidbdev.med.unc.edu/datab
ases/kidb.php
~10K compounds, 59K
interactions, 738 targets 2016
BindingDB Various bioactivities 
https://www.bindingdb.org/bind/i
ndex.jsp
~542K compounds, 1.2M 
activities, 5K targets 2016
PharmGKB Drug response data https://www.pharmgkb.org/ - 2016
Guide to 
Pharmacology Various bioactivities 
http://www.guidetopharmacology
.org/
~8K compounds, 14K
bioactivities, 2.7K targets 2016
DrugBank Drug/target interactions http://www.drugbank.ca/
~8K drugs, 15K drug/target 
associations, 4K targets 2016
CTD
Chemical-gene interactions, 
gene-disease and chemical-
disease associations
http://www.ctdbase.org/
~1.4M chemical-gene
interactions, 20M gene-
disease associations, 2M 
chemical-disease associations
2016
http://stitch.embl.de/
new beta: http://stitch-
beta.embl.de/
PubChem Various bioactivities 
https://pubchem.ncbi.nlm.nih.go
v/
~2M compounds, 230M 
bioactivities, 10K targets 2016
PHAROS Various bioactivities, target-
disease score 
https://pharos.nih.gov/
~134K compounds, 140K 
bioactivities, 1.8K targets, 
2.6K diseases
2016
Open Targets Target-disease and drug-
target associations
https://www.targetvalidation.org/
~2.1M target-disease
associations covering 7.9K 
diseases and 25K targets
2016
DGIdb Drug/gene interactions http://dgidb.genome.wustl.edu/
Without PharmGKB: ~12K 
compounds, 26K 
structure/gene pairs, ~3.1K 
targets
2016
CARLSBAD CARLSBAD activity http://carlsbad.health.unm.edu/
~435K structures, 933K 
structure/target pairs, 3.7K 
targets
2014
ChemProt ChemProt activity 
http://potentia.cbs.dtu.dk/ChemP
rot/
~1.7M structures, 7.8M 
structure/target pairs, 19K 
targets
2016
2016
interactions between 300K 
small molecules and 2.6K 
proteins from 1133 organisms
Association scoresSTITCH
uncommonly large effect. For most individuals with serious psychiatric disorders 262 
whose risk is mediated by the cumulative effect of large numbers of common genetic 263 
variant with or without important environmental impacts, it is not yet clear whether 264 
genomics will be an important part of precision medicine in psychiatry. We know that 265 
these genetic effects significantly impact risk 9,28 but the effects are not deterministic.  266 
An key approach is to use polygenic risk scores (extensively reviewed and discussed 267 
elsewhere 31). A polygenic risk score (PRS) 32 is an approximate measure of an 268 
individual’s common variant genetic propensity for a given disorder and, at a 269 
population level shows some predictive power 33 for case-control status. PRS 270 
approaches provide several potential routes to drug development, including 271 
identification of genetically associated endophenotypes and biomarkers. PRS can 272 
also be exploited to improve clinical trial efficacy. Super controls can be chosen by 273 
selecting participants with very low PRS for the disease, or PRS for low risk of side-274 
effects or where differential diagnosis is unclear. This may convey particular benefit 275 
in trials for diseases such as Alzheimer’s (being investigated by a new workgroup in 276 
the PGC), where defining cases and controls is challenging. Furthermore, prevention 277 
trials could enlist high risk individuals from the top end of the PRS distribution 34, 278 
which, amongst other benefits, may be less expensive and confounded than the 279 
sibling design 35. Current studies in psychiatry are attempting to improve prediction of 280 
diagnosis or treatment response, for example in first episode psychosis 36.  281 
PGC phase 3: Target identification in Psychiatric GWAS data. 282 
To fully exploit GWAS data for drug development, we need to complement the direct 283 
identification of single targets and their interactors and the use of polygenic risk 284 
scores with pathway-driven approaches, explicitly targeting sets of GWAS implicated 285 
regions/proteins together. In our view, this may be a powerful means to discover new 286 
drug indications/targets that gains power by exploiting the underlying polygenic 287 
nature of these disorders. This mirrors the observation that many successful 288 
psychiatric (and other) drugs have complex receptor pharmacology profiles binding 289 
multiple targets with different affinities. The PGC is planning to exploit pathway 290 
analysis methods37 that show better control for type 1 error alongside 291 
chemoinformatically generated gene sets to identify drugs or molecules with sets of 292 
targets significantly enriched for association in GWAS data. Applying drug pathway 293 
analyses to psychiatric GWAS results will allow us to derive hypotheses about drug 294 
mechanisms of action and rational drug repurposing 38. Rare variants, discovered by 295 
large scale sequencing efforts, can also be included in these analyses, particularly 296 
the known recurrent Copy Number Variations in Autism and Schizophrenia 39. These 297 
are complemented by ongoing large scale sequencing efforts in these disorders. 298 
Although rare mutations are only found in a small percentage of cases with most 299 
common disorder 40 41, integrative pathway analysis including common and rare 300 
variants might increase power to detect statistically significant enriched pathways. 301 
Using these data sources, three broad strategies are possible (see Figure 1). First, 302 
pathway analysis using the genetic variants found to be associated with psychiatric 303 
disorders using gene-sets (pathways) annotated for their drug associations or 304 
corresponding to sets of ligands in publically available resources such as ChEMBL 305 
and KiDB to test whether these gene sets together harbour a significant association 306 
signal using the PGC pathway analysis pipeline 42. Second, use relevant gene 307 
expression profiles identified from case-control transcriptome data and examine their 308 
similarity to induced gene expression changes in cell lines, as identified by the NIH 309 
LINCS project (URLs) or in studies of neuronal cells derived from iPSC, to identify 310 
potential pathways and molecules which impact the expression and/or function of 311 
identified targets 43. This strategy of ‘connectivity mapping’ allows identification of 312 
compounds with a similar or opposite effect on gene expression as our findings and 313 
can point to possible new treatment targets. Finally, we can layer onto these 314 
approaches “traditional” pathway annotations and ontologies (particularly GO and 315 
REACTOME) and newer data sources that may be less biased and more complete44 316 
to allow us to develop a mechanistic understanding.  317 
Conclusions 318 
These approaches require substantial and integrated efforts, involving consortia 319 
such as the PGC, other academic groups, and industry in pre-competitive framework 320 
to drive forward target identification and qualification to the point where confidence 321 
will be high enough to begin a clinical validation process; sharing of data and 322 
expertise will be essential. It will only be through collaborative work that the field will 323 
muster enough breadth of data and resources for this effort to fulfill its translational 324 
potential beyond polygenic risk score and prediction, to the identification of new 325 
biology and eventually towards resolving the current blockages in psychiatric drug 326 
discovery.   327 
 328 
 329 
Figure 1. PGC GWAS Drug Target Analysis Strategy: utilising diverse 330 
information sources for drug target discovery. 331 
 332 
URLs  333 
PGC (https://pgc.unc.edu), PHAROS (https://pharos.nih.gov), CHEMBL 334 
(https://www.ebi.ac.uk/chembl), Open Targets (https://www.targetvalidation.org), 335 
DGIdb (http://dgidb.genome.wustl.edu), CommonMind (http://commonmind.org), 336 
psychENCODE (http://psychencode.org), NIH LINCS (http://apps.lincscloud.org), GO 337 
project (http://geneontology.org/), REACTOME (http://www.reactome.org/), Pharos 338 
(https://pharos.nih.gov/), Open Targets (https://www.opentargets.org/). 339 
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Name Bioactivities Link Some Stats Last update
ChEMBL
Various 
bioactivities (Ki, 
EC50…)
https://www.ebi.ac.
uk/chembl/
~1.6M compounds, 
14M activities, 11K 
targets
2016
Ki DB Ki 
http://kidbdev.med.
unc.edu/databases/
kidb.php
~10K compounds, 
59K interactions, 
738 targets
2016
BindingDB Various bioactivities 
https://www.bindin
gdb.org/bind/index.
jsp
~542K compounds, 
1.2M activities, 5K 
targets
2016
PharmGKB Drug response data https://www.pharmgkb.org/ - 2016
Guide to 
Pharmacology
Various 
bioactivities 
http://www.guideto
pharmacology.org/
~8K compounds, 
14K bioactivities, 
2.7K targets
2016
DrugBank Drug/target interactions
http://www.drugba
nk.ca/
~8K drugs, 15K 
drug/target 
associations, 4K 
targets
2016
CTD
Chemical-gene 
interactions, gene-
disease and 
chemical-disease 
associations
http://www.ctdbase
.org/
~1.4M chemical-
gene interactions, 
20M gene-disease 
associations, 2M 
chemical-disease 
associations
2016
http://stitch.embl.de
/
new beta: 
http://stitch-
beta.embl.de/
PubChem Various bioactivities 
https://pubchem.nc
bi.nlm.nih.gov/
~2M compounds, 
230M bioactivities, 
10K targets 
2016
PHAROS
Various 
bioactivities, target-
disease score 
https://pharos.nih.g
ov/
~134K compounds, 
140K bioactivities, 
1.8K targets, 2.6K 
diseases
2016
Open Targets
Target-disease and 
drug-target 
associations
https://www.targetv
alidation.org/
~2.1M target-
disease associations 
covering 7.9K 
diseases and 25K 
targets
2016
DGIdb Drug/gene interactions
http://dgidb.genom
e.wustl.edu/
Without 
PharmGKB: ~12K 
compounds, 26K 
structure/gene 
pairs, ~3.1K targets
2016
2016
interactions 
between 300K 
small molecules 
and 2.6K proteins 
from 1133 
organisms
Association scoresSTITCH
CARLSBAD CARLSBAD activity
http://carlsbad.healt
h.unm.edu/
~435K structures, 
933K 
structure/target 
pairs, 3.7K targets
2014
ChemProt ChemProt activity http://potentia.cbs.dtu.dk/ChemProt/
~1.7M structures, 
7.8M 
structure/target 
pairs, 19K targets
2016
